指南与共识胃肠外科围术期管理与 ERAS

NCCN胃癌指南所引RCT证据稳健性的脆弱指数分析

Using the Fragility Index analysis for assessment of the robustness of evidence in randomized controlled trials cited in the NCCN guidelines for gastric cancer.
指南 / 共识 · Surgery · 2026-04-14

该研究系统评估了NCCN胃癌指南引用的30项随机对照试验(1998–2021年,共13,765例患者)的统计稳健性。结果显示,仅40%的试验报告了显著结果,其脆弱指数中位数为6(IQR 2–6),而反向脆弱指数中位数为8(IQR 3–17);辅助化疗的脆弱指数最高为20。研究表明指南推荐所依据的证据稳健性不足。

要点

  • NCCN胃癌指南引用的RCT中仅40%报告显著结果,脆弱指数中位数仅6。
  • 辅助化疗脆弱指数最高(20),其次为新辅助放化疗(8)和围手术期化疗(7)。
  • 外科试验平均失访9例,超过其脆弱指数8,提示证据稳健性存疑。

核心结论

  • NCCN胃癌指南推荐的治疗常基于主要终点无统计学显著性或脆弱指数低的RCT,证据强度令人担忧。

研究设计与样本

  • 系统综述NCCN最新胃癌指南引用的RCT,计算主要二分类结局的脆弱指数与反向脆弱指数。
  • 共分析30项RCT(1998–2021年),纳入13,765例患者,每项研究中位430例。
  • 93.3%的研究以总生存为主要终点。

主要发现

  • 仅40%的研究报告统计学显著结果,其脆弱指数中位数为6(IQR 2–6)。
  • 未达显著性的研究中,反向脆弱指数中位数为8(IQR 3–17)。
  • 辅助化疗脆弱指数最高为20,新辅助放化疗为8,围手术期化疗为7。
  • 单纯化疗试验的反向脆弱指数最低为27.5。
  • 外科研究平均失访9例,超过其脆弱指数8。

临床怎么用

  • 解读NCCN胃癌指南推荐时需关注其证据稳健性,脆弱指数低的试验结论应谨慎应用。
  • 外科相关试验中失访数超过脆弱指数,提示需重视患者随访完整性对结论的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The National Comprehensive Cancer Network guidelines are based on randomized controlled trials that support treatment recommendations. The Fragility Index measures the minimum number of patient outcomes needed to alter or overturn a trial's statistical significance. In contrast, the Reverse Fragility Index indicates the minimum changes required to achieve significance in trials that initially show nonsignificant results. This study aimed to assess the robustness of randomized controlled trials cited in the National Comprehensive Cancer Network guidelines for gastric cancer, using both the Fragility Index and the Reverse Fragility Index. METHODS: We systematically reviewed randomized controlled trials referenced in the latest National Comprehensive Cancer Network guidelines for gastric cancer. The Fragility Index and Reverse Fragility Index were calculated for primary binary outcomes. Robustness was further assessed by comparing Fragility Index/Reverse Fragility Index values with the number of patients lost to follow-up. RESULTS: We analyzed 30 randomized controlled trials conducted between 1998 and 2021, which included 13,765 patients, with a median of 430 patients per study. Overall survival was the primary endpoint in 93.3% of the studies. Only 40% of the studies reported statistically significant results, with a median Fragility Index of 6 (interquartile range = 2-6). In contrast, among the studies that did not achieve statistical significance, the median Reverse Fragility Index was 8 (interquartile range = 3-17). Adjuvant chemotherapy had the highest Fragility Index at 20, followed by neoadjuvant chemoradiotherapy, with a Fragility Index of 8, and perioperative chemotherapy with a Fragility Index of 7. On the other hand, trials involving chemotherapy alone had the lowest Reverse Fragility Index of 27.5. Surgical studies averaged 9 patients lost to follow-up, exceeding their Fragility Index of 8, highlighting inconsistencies in study integrity and patient retention. CONCLUSION: The study indicates that the treatments recommended in the National Comprehensive Cancer Network guidelines for gastric cancer are often based on randomized controlled trials with nonsignificant primary outcomes and low Fragility Indices, raising concerns about the strength of the evidence.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Kahana N, Boaz E, Horesh N, et al. Using the Fragility Index analysis for assessment of the robustness of evidence in randomized controlled trials cited in the NCCN guidelines for gastric cancer. Surgery. 2026. PMID: 42463264. doi:10.1016/j.surg.2026.110176

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。